Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 241 West Huaihai Road, Shanghai, 200030, China.
Radiat Oncol. 2024 Sep 27;19(1):130. doi: 10.1186/s13014-024-02528-0.
This study aims to delineate the long-term outcomes and recurrence patterns of locally advanced thoracic esophageal squamous cell carcinoma (TESCC) patients managed with or without postoperative radiotherapy (PORT).
A retrospective cohort from two academic centers, encompassing patients who initially underwent esophagectomy and were pathologically staged T3-4, was analyzed. Survival outcomes were constructed using Kaplan-Meier method, with survival significance was evaluated using the log-rank test. Propensity score matching (PSM) was utilized to balance potential selection bias.
Among the 506 patients, 251 underwent surgery alone and 255 received radiotherapy following radical surgery. With a median follow-up of 49.1 months, PORT significantly improved 5-year overall survival (53.8% vs. 25.3%; p < 0.001) and 5-year disease-free survival rates (45.3% vs. 8.5%; p < 0.001) compared to surgery alone. These differences in survival outcomes persisted even after PSM (p < 0.001 for both). Treatment failure was significantly less frequent in the PORT group (46.7%) compared to the surgery-only group (90.0%; p < 0.001), with corresponding reductions in locoregional recurrence (9.4% vs. 54.1%; p < 0.001). This underscores the significant association between PORT and disease control.
The absence of neoadjuvant chemoradiotherapy highlights the importance of PORT in improving survival and reducing recurrence in advanced T3-4 TESCC patients. This study underscores the importance of PORT as a salvage treatment for locally advanced TESCC patients without neoadjuvant chemoradiotherapy.
本研究旨在描绘接受或不接受术后放疗(PORT)的局部晚期胸段食管鳞癌(TESCC)患者的长期结局和复发模式。
对来自两个学术中心的回顾性队列进行分析,纳入初始接受食管切除术且病理分期为 T3-4 的患者。采用 Kaplan-Meier 方法构建生存结局,使用对数秩检验评估生存意义。采用倾向评分匹配(PSM)平衡潜在选择偏倚。
在 506 例患者中,251 例患者仅接受手术,255 例患者在根治性手术后接受放疗。中位随访时间为 49.1 个月,PORT 显著提高了 5 年总生存率(53.8% vs. 25.3%;p<0.001)和 5 年无病生存率(45.3% vs. 8.5%;p<0.001),与单纯手术相比。即使在 PSM 后,这些生存结局的差异仍然存在(均 p<0.001)。PORT 组的治疗失败率明显低于单纯手术组(46.7% vs. 90.0%;p<0.001),相应的局部区域复发率也降低(9.4% vs. 54.1%;p<0.001)。这突显了 PORT 与疾病控制之间的显著关联。
未行新辅助放化疗凸显了 PORT 在改善生存和降低局部晚期 T3-4 TESCC 患者复发方面的重要性。本研究强调了 PORT 作为局部晚期 TESCC 患者在未行新辅助放化疗时的一种挽救性治疗的重要性。